You can buy or sell PBYI and other stocks, options, ETFs, and crypto commission-free!
Puma Biotechnology Inc Common Stock, also called Puma Biotechnology, is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. Read More The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Los Angeles, California
52 Week High
52 Week Low
Seeking AlphaMay 10
Puma Biotechnology, Inc. CEO Alan Auerbach on Q1 2019 Results - Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2019 Results Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - President & Chief Executive Officer Steve Lo - Chief Commercial Officer Maximo Nougues - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Varun Kumar - Cantor Fitzgerald Corinne Jenkins - Goldman Sachs Chris Shibutani - Cowen Kennen MacKay - RBC Capital Markets Michael Schmidt - Guggenh...
Yahoo FinanceMay 10
Puma Biotech Q1 Earnings Top, Nerlynx Disappoints
Puma Biotechnology, Inc. PBYI incurred a loss of 26 cents per share for the first quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 69 cents as well as the year-ago loss of 65 cents. Total revenues consist of both net product revenues from the sales of Nerlynx (neratinib) and the company’s license revenues. In the first quarter of 2019, total revenues came in at $99.1 million, comprising $45.6 million of product revenues from Nerlynx and $53.5 million of license revenues. Moreover, s...
-$0.68 per share
-$0.26 per share